<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422888</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10048</org_study_id>
    <secondary_id>2014-005363-33</secondary_id>
    <nct_id>NCT02422888</nct_id>
  </id_info>
  <brief_title>Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor</brief_title>
  <acronym>REDUCE-MVI</acronym>
  <official_title>Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial will compare the protective effect of ticagrelor and prasugrel on&#xD;
      microvascular dysfunction in patients with revascularized ST elevation myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary microvascular dysfunction is highly prevalent in revascularized ST-elevation&#xD;
      myocardial infarction and has important prognostic implications. Current data suggest that&#xD;
      ticagrelor might be superior to prasugrel in the reduction of coronary microvasculature&#xD;
      dysfunction. Thus, we have designed a clinical trial that will compare microvascular function&#xD;
      in revascularized ST-elevation myocardial infarction patients at treatment steady state with&#xD;
      ticagrelor or prasugrel. Coronary microvascular dysfunction will be assessed with the index&#xD;
      of microcirculatory resistance after primary percutaneous coronary intervention and at 1&#xD;
      month follow-up in the infarct-related vessel and non-infarct related vessel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microcirculatory resistance (IMR)</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured in the infarct-related artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta Index of microcirculatory resistance (IMR)</measure>
    <time_frame>Baseline vs. 1 month follow-up</time_frame>
    <description>measured in the infarct-related artery and non-infarct related artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reactive hyperemia index (RHI)</measure>
    <time_frame>1 month and 1 year after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (LVEF) recovery</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction</measure>
    <time_frame>3 days after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymmetric Dimethylarginine (ADMA) levels</measure>
    <time_frame>1 month after primary PCI</time_frame>
    <description>Blood measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-myocardial haemorrhage</measure>
    <time_frame>3 days after primary PCI</time_frame>
    <description>measured with MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent&#xD;
&#xD;
          2. Patients presenting with ST-elevation myocardial infarction &lt;12 hours after symptom&#xD;
             onset&#xD;
&#xD;
          3. Successful percutaneous coronary intervention of the infarct-related vessel with a&#xD;
             modern drug-eluting stent&#xD;
&#xD;
          4. Intermediate stenosis in non-infarct-related vessel (50-90%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of myocardial infarction&#xD;
&#xD;
          2. Participation in another clinical study with an investigational product during the&#xD;
             preceding 30 days&#xD;
&#xD;
          3. history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA)&#xD;
&#xD;
          4. History of intracranial haemorrhage&#xD;
&#xD;
          5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol)&#xD;
&#xD;
          6. severe liver dysfunction (Child-Pugh score 10-15)&#xD;
&#xD;
          7. congestive heart failure&#xD;
&#xD;
          8. cardiogenic shock&#xD;
&#xD;
          9. left ventricular ejection fraction &lt; 35%&#xD;
&#xD;
         10. bleeding diathesis&#xD;
&#xD;
         11. age â‰¥ 75 or &lt; 18&#xD;
&#xD;
         12. body weight &lt; 60 kg&#xD;
&#xD;
         13. gout&#xD;
&#xD;
         14. coagulation disorders&#xD;
&#xD;
         15. severe pulmonary disease&#xD;
&#xD;
         16. pregnancy and breast feeding&#xD;
&#xD;
         17. limited life expectancy&#xD;
&#xD;
         18. platelet count &lt; 100 000/mm3&#xD;
&#xD;
         19. history of drug addiction or alcohol abuse in the past 2 years&#xD;
&#xD;
         20. need for chronic nonsteroidal anti-inflammatory drug&#xD;
&#xD;
         21. creatinine clearance &lt;30 mL/min or dialysis&#xD;
&#xD;
         22. chronic total occlusion (CTO)&#xD;
&#xD;
         23. Left main disease&#xD;
&#xD;
         24. allergy or contra-indication for ticagrelor or prasugrel&#xD;
&#xD;
         25. Contra-indication for adenosine&#xD;
&#xD;
         26. Patients unable to be followed on-site&#xD;
&#xD;
         27. Unable to undergo or contra-indications for MRI&#xD;
&#xD;
         28. Contra-indication for drug-eluting stent&#xD;
&#xD;
         29. Inability to obtain informed consent&#xD;
&#xD;
         30. Coronary artery bypass grafting in medical history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Maarten van Leeuwen</investigator_full_name>
    <investigator_title>Study coordinator</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

